Article

Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin - Ocular safety pilot results

Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 90 Bergen Street, Newark, NJ 07103, USA.
Archives of Ophthalmology (Impact Factor: 4.49). 10/2006; 124(9):1257-62. DOI: 10.1001/archopht.124.9.1257
Source: PubMed

ABSTRACT To evaluate the ocular safety of short-term use of vigabatrin to treat cocaine and/or methamphetamine addiction.
Individuals who were actively using cocaine and/or methamphetamine were eligible for enrollment. Enrolled subjects were scheduled for comprehensive eye examinations at the beginning and end of the study. Visual field testing was performed at baseline and 1 week, 4 weeks, 8 weeks, and 1 month or more after discontinuing vigabatrin. Twenty-eight subjects received at least 1 dose of vigabatrin; however, only 20 subjects continued beyond the initial escalating vigabatrin dose phase to the treatment phase. Of these 20 subjects, 18 completed the study with full follow-up. Visual fields were evaluated subjectively by 2 glaucoma specialists and analyzed objectively for group and individual changes in quadrant mean sensitivity. The objective analysis was also repeated for superior field quadrants after excluding the uppermost peripheral points to minimize the eyelid effect. The main outcome measures were change of visual field, visual acuity, and ocular adverse effects.
Vigabatrin seemed to help treat cocaine and/or methamphetamine addiction. Of 18 subjects, 16 had negative test results for cocaine and methamphetamine use during the last 6 weeks of the trial. No ocular adverse events were detected. The subjective evaluation did not reveal visual field constriction in any of the 18 evaluable participants. Objective group and individual analyses for quadrant mean sensitivity did not show any change from baseline in any quadrant. No changes in visual acuity were noted.
In this short-term pilot study, vigabatrin seemed to help treat cocaine and/or methamphetamine abuse. There was no evidence of ocular or visual field adverse effects.

0 Bookmarks
 · 
112 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CONTEXTO: Tem sido sugerido que durante as crises convulsivas induzidas pela pilocarpina pode ser observado aumento no estresse oxidativo cerebral. Estudos sugerem que compostos com atividade antioxidante podem fornecer certo grau de proteção contra a neurotoxicidade induzida pelas crises convulsivas. OBJETIVOS: O presente estudo investigou as ações farmacológicas da vigabatrina nas alterações comportamentais e na atividade enzimática da superóxido dismutase (SOD) no corpo estriado de ratos adultos. MÉTODOS: Ratos Wistar adultos (2 meses de idade) foram usados nos experimentos e divididos em quatro grupos. O primeiro foi tratado com solução salina 0,9% (grupo controle). O segundo grupo foi tratado com pilocarpina (400 mg/kg, i.p., grupo P400). O terceiro grupo foi tratado com vigabatrina (500 mg/kg, i.p., grupo VGB) e o quarto grupo foi tratado com vigabatrina (500 mg/kg, i.p.) e 30 minutos depois com pilocarpina (400 mg/kg, i.p., grupo VGB + P400). Os animais que apresentaram crises convulsivas, estado de mal epiléptico e não morreram durante o período de 24 horas de observação foram sacrificados para dissecação do corpo estriado para realização da determinação da atividade da SOD. RESULTADOS: Os estudos comportamentais revelaram que, após administração de pilocarpina, todos os animais apresentaram sinais colinérgicos periféricos, movimentos estereotipados e tremores. No mesmo grupo, foram observados, em 75% dos animais, crises convulsivas e o estado de mal epiléptico. Por sua vez, o pré-tratamento com vigabatrina produziu redução significativa de 50% nas crises convulsivas. Com relação aos estudos neuroquímicos, não foram observadas alterações na atividade da SOD no corpo estriado do grupo P400, em comparação aos valores do grupo controle. No entanto, no grupo VGB + P400 foi visto aumento significativo na atividade da SOD de 34% e 35%, quando comparado aos grupos controle e P400, respectivamente. CONCLUSÕES: Os resultados do presente estudo indicam que durante as crises convulsivas ocorrem alterações comportamentais, entretanto, não foram verificadas mudanças na atividade da SOD durante a fase aguda dessas crises. Esses dados sugerem que os efeitos anticonvulsivantes da vigabatrina podem ser decorrentes da neuromodulação da SOD. No entanto, serão realizados novos estudos neurofarmacológicos para o esclarecimento do mecanismo de ação da vigabatrina no modelo de epilepsia induzido pela pilocarpina.
    Revista de Psiquiatria Clínica 01/2010; 37(1):36-40. DOI:10.1590/S0101-60832010000100008 · 0.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IMPORTANCE Cocaine dependence is a significant public health problem, yet no validated pharmacological treatment exists. The potent γ-aminobutyric acid (GABA)ergic medication vigabatrin has previously been shown to be effective in a double-blind single-site study conducted in Mexico. OBJECTIVE To evaluate the safety and efficacy of vigabatrin for the treatment of cocaine dependence in a US sample. DESIGN AND SETTING Multisite, randomized, double-blind, placebo-controlled, 12-week clinical trial with follow-up visits at weeks 13, 16, 20, and 24 in 11 US sites. PARTICIPANTS In total, 186 treatment-seeking participants with cocaine dependence (mean age, 45 years). Approximately 67% were male, and about 60% were of African American race/ethnicity. INTERVENTIONS Participants received twice-daily doses of vigabatrin (total dosage, 3.0 g/d) or matched placebo, plus weekly computerized cognitive behavioral therapy and biweekly individual counseling for 13 weeks. Contingency management encouraged the provision of urine samples. MAIN OUTCOMES AND MEASURES The primary outcome measure was the proportion of participants with cocaine abstinence during the last 2 weeks of the 12-week treatment phase as assessed by self-reports and quantitative urine drug screens. The weekly fraction of cocaine use days and the number of drug-free urine samples during weeks 1 through 13 were key secondary measures. RESULTS No significant differences were observed between the vigabatrin group and the placebo group on the primary outcome measure (P = .67), key secondary measures (P > .99), or other outcome measures. However, while pill counts and self-reports indicated that more than 66% of all participants (and >63% of the vigabatrin group) took more than 70% of their medication, post hoc vigabatrin urine concentration levels suggested that approximately 40% to 60% of patients taking vigabatrin may not have been adherent. This lack of adherence may have obscured any evidence of vigabatrin efficacy. No visual acuity or visual field deterioration occurred in any of the participants. CONCLUSIONS AND RELEVANCE No protocol-defined differences in efficacy between vigabatrin treatment and placebo were detected for any outcome variable. This may have been due to medication nonadherence or, alternatively, due to the weak efficacy of vigabatrin. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00611130.
    JAMA Psychiatry 04/2013; 70(6):1-8. DOI:10.1001/jamapsychiatry.2013.872 · 12.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The antiepileptic drug vigabatrin has been used widely since 1989, but has only been approved for use in the US since 2009. The risk:benefit of vigabatrin is generally predicated upon an assumed frequency of associated visual field loss (VAVFL) of approximately 31 %. This estimate is based upon relatively short-term usage (up to 4-5 years) and it is essential to determine whether the frequency of VAVFL increases with longer-term usage. The aim of this study was to model, from cross-sectional evidence, over greater ranges of treatment duration and cumulative dose than previously evaluated, the risk (frequency) of VAVFL with increasing exposure to vigabatrin. This was a retrospective cohort study undertaken in a regional hospital epilepsy clinic. The cohort comprised 147 consecutive patients treated with vigabatrin for refractory complex partial (focal) seizures, who had all undergone ophthalmological examination and who had undertaken perimetry, reliably, according to a standard and robust protocol. The visual field plots were evaluated masked to treatment duration and dose. The risk (frequency) of VAVFL with increasing exposure to vigabatrin was modelled, from the cross-sectional evidence, by standard and plateau logistic regression. The cohort comprised 80 females and 67 males (mean age 40.3 years, standard deviation 13.7). The median duration of vigabatrin exposure was 7.9 years (interquartile range 3.6-11.0, range 0.2-16.1 years); 46 patients (31 %) had received vigabatrin for over 10 years. Eighty-seven patients (59 %) exhibited VAVFL; the proportion with VAVFL was higher in males (66 %) than females (54 %). The plateau model for duration and for cumulative dose exhibited a better fit than the standard model (both p < 0.001). The modelled frequency of VAVFL increased with increasing exposure up to approximately 6 years duration and 5 kg cumulative dose, and plateaued at approximately 76 % (95 % CI 67-85) and 79 % (95 % CI 70-87), respectively. Severity of VAVFL, classified in terms of the visual field index Mean Deviation, was not significantly associated with either duration or cumulative dose of therapy. Clinicians and patients, in enabling informed choice, should be alert to the possible substantial increased risk:benefit for VAVFL with increasing long-term exposure to vigabatrin and the ensuing increased cost:benefit resulting from the necessary additional visual assessments.
    CNS Drugs 08/2013; 27(10). DOI:10.1007/s40263-013-0100-z · 4.38 Impact Factor

Full-text (2 Sources)

Download
73 Downloads
Available from
May 19, 2014